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OBJECTIVE — To quantify the incremental survival beneﬁt of the pancreas allograft in si-
multaneous pancreas-kidney (SPK) transplant recipients.
RESEARCH DESIGN AND METHODS — Data from the national transplant database
from 2000 to 2007 were analyzed. SPK recipients who had functioning allografts to 1-year post
transplant (n  3,304) were compared with those who had failure of the renal (n  233) or
pancreatic(n112)graft.Themainoutcomewasaprojectionof10life-yearsofpatientsurvival
beyond the ﬁrst transplant anniversary.
RESULTS — Recipients with function of both organs accrued 9.4 life-years following trans-
plantation. Projected survival in patients with kidney failure was reduced to 2.5 life-years.
Pancreas failure reduced predicted survival to 8 life-years. Renal allograft failure impacts life
expectancysigniﬁcantly(adjustedhazardratio[aHR]12.13).However,pancreasallograftfailure
was also associated with reduced survival (aHR 2.62).
CONCLUSIONS — Although the majority of the survival beneﬁt of SPK transplant is due to
the renal transplant, pancreas allograft function does contribute to patient survival.
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T
he American Diabetes Association
considers simultaneous pancreas-
kidney (SPK) transplantation the
treatment of choice for patients with type
1 diabetes and chronic renal failure (1).
Previous studies have questioned the in-
crementalbeneﬁtofthepancreasallograft
compared with kidney transplant alone
for the uremic diabetic patients (2–9).
This study aims to quantify the incre-
mental value of the pancreas allograft
function to the survival of SPK trans-
plant recipients.
RESEARCH DESIGN AND
METHODS— A retrospective cohort
study of all SPK transplant recipients be-
tween 1 January 2000 and 31 December
2007 was performed utilizing data from
the Organ Procurement and Transplanta-
tion Network (OPTN) research ﬁles.
Adult (age 18 years), ﬁrst-SPK trans-
plant recipients with chronic renal failure
duetotype1diabeteswereincluded.The
primary outcome was projected incre-
mental life-years attributed to each al-
lograft’s function based on data from
recipients of SPK transplantation with
dual function (n  3,304), isolated kid-
ney graft failure (n  233), or pancreas
graft failure (n  112) (10).
Perioperative mortality risk increases
the hazard of death early after transplant,
complicating the projection of long-term
survival with a single mathematical func-
tion. We utilized a two-part strategy to
quantify the implications of organ-
speciﬁc allograft failure on patient sur-
vival.First,weestimatedtheindependent
associations of kidney and pancreas fail-
ure with relative mortality risk (adjusted
hazard ratio [aHR]) by multivariable Cox
regression, using 5 years of observed reg-
istry data. We then computed long-term
survival expectations by parametric re-
gression assuming a Weibull survival
function. Survival expectation of patients
who sustained function of both organs
was estimated as the reference by censor-
ing of time to death at the ﬁrst occurrence
ofkidneyorpancreasfailure,andthearea
under a 10-year survival projection be-
yond the ﬁrst transplant anniversary was
computed as the life-years expectancy
over 10 years. The daily mortality hazard
in the reference group was computed as
the difference in projected survival be-
tween day x and day x  1. Survival ex-
pectations with organ-speciﬁc graft
failurewerequantiﬁedbymultiplyingref-
erence group daily hazards by the associ-
ated relative hazard ratio computed for
graft failure using Cox regression analysis
and sequentially subtracting estimated
survival decrements at each day over 10
years.
RESULTS— Survival was projected
for 3,649 SPK recipients who survived
with functioning allografts to the ﬁrst an-
niversary following SPK over a possible
10-year time horizon. The long-term
mortality impact of transplant failure is
substantially greater following kidney
failure (aHR 12.13 for death 30 days
after organ failure) than after pancreas
failure(aHR2.62fordeath30daysafter
organ failure).
In our projection, loss of both kidney
andpancreasallograftfunctionhadasub-
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for SPK patients over the 10 years post
transplantation (Fig. 1). Overall, recipi-
ents of SPK transplants who had kidney al-
lograft failure lost 6.9 of the 9.4 life-years
expected for patients with preserved func-
tion of both organs. Pancreas allograft fail-
urewasassociatedwithareductionof1.4of
the 9.4 life-years expected after SPK trans-
plantation with long-term sustained func-
tion of both grafts. Thus, kidney failure
reduced expected survival by 85%, while
pancreas loss reduced projected survival by
15% among SPK recipients.
CONCLUSIONS — Understanding
the independent value of the pancreas al-
lograft is vital to the assessment of the
beneﬁts of SPK transplantation and as-
sessmentofallocationpolicy.Wechoseto
begin the analysis after 1 year to avoid the
initial postoperative period, when most
surgical and medical complications often
occurbutmostofthebeneﬁtshavenotyet
accrued (8,11). The timing of graft failure
events might impact the calculation of
life-years gained from a transplant; how-
ever,inourpilotstudies,itdidnotmodify
the main results herein presented.
We have demonstrated that although
the likelihood of death after allograft fail-
ure is substantially greater following kid-
ney failure, pancreas loss does have a
detrimental impact on patient survival.
This analysis is limited by our inability to
determine whether the reduction in sur-
vivalwastheresultofacomplicationfrom
thegraftlossitselforfromthelossoffunc-
tion over time. The natural experiment
observed using this method eliminated
themajorweaknessesofpreviousstudies:
selection bias of comparison of SPK and
isolated renal transplant recipients who
maydifferinbothpatientanddonorchar-
acteristics(2–9).Onecouldarguethatthe
independent value of each allograft might
be difﬁcult to isolate because of the inter-
active processes between both organs
(such as a reduction in rejection due to
the presence of an additional organ).
However, we did not ﬁnd any data docu-
menting this effect.
We estimated the kidney and pan-
creasallograftfunctiontocontribute85
and 15%, respectively, to the expected
patient life-years survival beneﬁt of SPK
transplantation. There is clearly an iden-
tiﬁable, independent life-years beneﬁt
from the pancreas allograft. Based on our
data, launching of new allocation policies
that will augment the volume of SPK
transplantation should be supported.
In addition to the known limitations
of retrospective registry studies, our ﬁnd-
ings have other limitations. The OPTN
Registry does not carry indexes of glyce-
mic control. This prevents analysis of the
relationship between strict normoglyce-
mia and pancreas allograft life-years gain.
Wehavenotincludedtheimpactonqual-
ity of life produced by differential allo-
graft survival in speciﬁc clinic scenarios,
suchaspatientswithbrittlediabetes(12).
Finally, there are inherent methodologi-
cal limitations of any attempt to predict
future outcomes based on available data
and assumptions. However, similar pro-
jections have performed well compared
withactualoutcomes,suggestingthatthis
method is robust.
Insummary,themajorityoflife-years
gained following SPK is related to pre-
served renal allograft function. The pan-
creas allograft appears to have an
important, but smaller, independent role
in adding life-years for type 1 diabetic pa-
tients with chronic renal failure.
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